Form 4: Coherus BioSciences Director Acquires Stock Options
SEC Form 4 Filing
Georgia Erbez, a director at Coherus BioSciences, acquired stock options for 114,000 shares on June 4, 2024.
Summary
- On June 4, 2024, Georgia Erbez, a director of Coherus BioSciences, Inc., acquired stock options for 114,000 shares.
- The exercise price of these options is $1.78.
- The options vest over three years, with one-third vesting on June 4, 2025, and the remainder vesting monthly thereafter, contingent upon continued service.
- Following the transaction, Erbez directly owns options for 114,000 shares of Coherus BioSciences common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director acquiring stock options suggests confidence in the company, but it's a routine transaction.
Positives
- A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/04/2024 | Date of the stock option acquisition. |
| 06/04/2024 | Date of the earliest transaction. |
| 06/04/2025 | First vesting date for 1/3rd of the stock options. |
| 06/04/2034 | Expiration date of the stock options. |
| 06/05/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.